Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-11. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
=== Subgroups or clusters within FM === There may be clusters of symptom characteristics within fibromyalgia. A 2024 systematic review found that fibromyalgia could be clustered according to symptom severity, adjustment to the condition, thermal pain sensitivity, personality, and response to treatment. However it stated there was a need for more objective measures, and for more validation and replication of clusters. Clustering has also been undertaken based on psychological and coping characteristics of FM people.
=== Spectroscopy === In chemistry, spectroscopy is used to analyze products of reactions. To understand if dexamethasone is synthesized from a reaction, spectroscopy must be taken and compared to the literature spectrum. There are multiple spectroscopy analyses that can be taken including 1H NMR, 13C NMR, IR, Mass spectrometry, and UV/vis spectroscopy. Using IR spectroscopy, the peaks show the functional groups found in the molecule. Peaks at 3472, 1662, and 1618 represent alcohol, aldehyde, and alkene functional groups. UV-vis spectroscopy is another way to analyze a product to figure out what it is. Finally, mass spectroscopy showed peaks at: 393.1, 355.2 147.1 m/z. The peak at 393.1 m/z is the peak for dexamethasone as its molecular weight is 392.46 m/z.
=== Sports journalists === Jeremy Gaige (1951), chess archivist and journalist Paul Zimmerman (1955), football writer for Sports Illustrated known as "Dr. Z" Robert Lipsyte (1957), sports writer for The New York Times, correspondent for ABC News and host of The Eleventh Hour Chet Forte (1957), first director of Monday Night Football Steven Krasner (1975), sports journalist famous for covering the Boston Red Sox for The Providence Journal 1986–2008 Bob Klapisch (1979), sports writer for The Record and Fox Sports Gary Cohen (1981), television play-by-play announcer for the New York Mets
Sources: en.wikipedia.org
== Diagnosis == Since arteritic AION is similar in presentation to non-arteritic AION, patients over the age of 50 diagnosed with NAION must be evaluated to exclude AAION (symptoms: painful jaw muscle spasms, scalp tenderness, unintentional weight loss, fatigue, myalgias and loss of appetite); NAION patients over the age of 75 should always be tested. The distinction between AAION and non-arteritic AION was made to highlight the different etiologies of anterior ischemic optic neuropathy. AAION is due to temporal arteritis (also called giant-cell arteritis), an inflammatory disease of medium-sized blood vessels (Chapel-Hill-Conference) that occurs especially with advancing age. In contrast, NAION results from the coincidence of cardiovascular risk factors in a patient with "crowded" optic discs. Non-arteritic AION is more common than AAION and usually occurs in slightly younger persons. While only a few cases of NAION result in near total loss of vision, most cases of AAION result in nearly complete vision loss. Nonarteritic anterior ischemic optic neuropathy is an isolated white-matter stroke of the optic nerve (ON). NAION is the most common cause of sudden optic nerve-related vision loss, affecting more than 10,000 Americans every year, often bilaterally. No clinically effective treatments exist, largely because little is known about its pathophysiology, and there are few histopathological studies of the acute condition.
== The Medical Sciences Club of South Australia == The Medical Sciences Club of South Australia, one of the oldest scientific clubs in Australia, was founded in Adelaide in 1920 as a means through which researchers in the sciences considered fundamental to medicine and medical practitioners interested in those aspects of medicine could regularly come together for their mutual benefit and for the advancement of biological and medical science. The club's inaugural meeting was held at the University of Adelaide on 16 April 1920. The fourteen medical men and scientists who attended the meeting were: Mr. Lionel Bull; Dr. Trent Champion de Crespigny; Dr. Raphael Cilento; Professor John Burton Cleland; Dr. Henry Fry; Dr. Frank Hone; Professor F. Wood Jones; Dr. Henry S. Newland; Dr. Robert Pulleine; Dr. William Ray; Professor Edward Rennie; Professor T. Brailsford Robertson; Dr. Malcolm Leslie Scott, M.B. B.S., M.R.C.S., F.R.C.S., M.Ch. (1882–1931); and Dr Harry Swift. The meeting appointed Dr Harry Swift as the club's temporary chairman, and Brailsford Robertson as its temporary secretary. Aside from its regular monthly meetings, the club was responsible for the on-going, quarterly publication of The Australian Journal of Experimental Biology and Medical Science from its first issue (March 1924) until its last issue (December 1986), after which it was re-named Immunology & Cell Biology.
13 March – Five people are taken to hospital for treatment after a bus crashes into a high rise block of flats in Paisley, Glasgow. 14 March – The Scottish Parliament Corporate Body finds Michael Matheson in breach of the Ministerial Code over his £11,000 iPad bill. Mountaineer Anna Wells becomes the first woman to reach the top of all of Scotland's 282 Munros in one winter season. 15 March – Following trial and conviction at the High Court in Glasgow, double murderer Peter Duffy is sentenced to at least 30 years in prison for the murder of his wife, Emma Baillie, and brother, John-Paul Duffy, in separate incidents in Coatbridge in 2022. 17 March – HMP Kilmarnock becomes the first privately run prison in Scotland to pass into the ownership of the Scottish Prison Service after its contract with Serco comes to an end. 19 March – Scottish Prison Service director Allister Purdie gives evidence to the Scottish COVID-19 Inquiry, and apologises to the family of Callum Inglis, who died at Addiewell Prison during the pandemic, after his family learned of the death through word of mouth before they were told formally by prison authorities. 21 March – The Scottish Parliamentary Corporate Body confirms that members of Scottish Parliament staff will no longer be allowed to wear rainbow lanyards, or any other badge or jewellery associated with social issues, while at Holyrood. The Wildlife Management and Muirburn (Scotland) Bill passes its final vote in the Scottish Parliament.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.